You are the technical supervisor of the blood bank. One of…
You are the technical supervisor of the blood bank. One of your techs suggests that it would be more cost effective to perform antibody screening on patients using commercially available pooled reagent red blood cells rather than a three-cell screen. The tech reasons that the pooled reagent requires only one gel well for testing versus three wells for the typical screen cells. This would mean cost savings! Is it acceptable to use pooled screening cells for patient pre-transfusion testing? Why or why not?
Read DetailsYou have determined antibody specificity based on ruling out…
You have determined antibody specificity based on ruling out using panel cells that did not react. Explain how you have ruled in suspected antibody(ies) in this case. Is there additional testing that needs to be done to reach a conclusion?
Read DetailsA type-A person demonstrates a 3+ reactivity with A1 cells (…
A type-A person demonstrates a 3+ reactivity with A1 cells (reverse grouping). The forward grouping with anti-A is 4+. Therefore, the possibility of a subgroup is excluded. B cells demonstrate a 4+ reaction. The antibody screen is weakly positive at 37°C, but shows no reactivity at the AHG phase. An antibody panel is performed and anti-M is identified. The patient phenotypes negative for M antigen. How is the ABO discrepancy resolved?
Read Details